Skip to content

Occurance of residual neuromuscular blockade in patients received general anesthesia

Occurance of residual neuromuscular blockade in patients received general anesthesia - General aneshtesia and residual neuromuscular blockade

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000002639
Enrollment
25
Registered
2009-10-18
Start date
2009-10-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diseases which need operation under general anesthesia

Interventions

conditions. Either inhalational anesthesia or TIVA is used. 2. Tracheal intubation is done after adequate dose of rocronium is injected. 3. Intraoperative rocuronium useage is determined by the anes
0.9, the reversal is considered once agein and the respiratory condition is checkd. When the reversal agent is administered once again, another TOF ratio is measured.

Sponsors

4 University investigation of neuromuscular blockade
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Patients, aged 20 or over (ASA phisical status 1-3) and who is operated under general anesthesia using rocuronium.

Exclusion criteria

Exclusion criteria: Patients who have a history of hypersensitivity to rocuronium and bromide. Patients who have myasthenia gravis and myasthenic syndrome.

Design outcomes

Secondary

MeasureTime frame
1. Total rocuronium dose 2. Time from extubation to measurement of TOF ratio 3. Time from latest rocuronium use to extubation 4. Time from administration of reversal agent to extubation 5. The difference of TOF ratio between existence or nonexistence of reversal agent 6. The difference of TOF ratio among the anesthetic managements

Primary

MeasureTime frame
The number of patients whose TOF ratio <0.9 after tracheal extubation

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026